Gilead Sciences receives Priority Review for Bulevirtide (HEPCLUDEX) BLA761468
Gilead Sciences has submitted Biologics License Application (BLA761468) for Bulevirtide (HEPCLUDEX) with Priority Review status.
Indication
Clinical and regulatory intelligence for Hepatitis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.